Últimas noticias sobre Boqii Holding (AMEX:BQ) Bolsa

Boqii Holding

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

Boqii Holding Limited American Depositary Shares (each representing one hundred fifty (150) Class A Ordinary Shares)

Boqii Holding Ltd

BANK AUDI SAL S/GDR 144A by Bank Audi SAL

Bank Audi SAL

BANQUE CANTNLE VDOISE NEW by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise

Bank of Africa

Boss Energy Ltd

BioQuest Corp

&nbsp;ASA's Readoption of the Poison Pill Followed the Court's March 28th Ruling that the Pill Violates the Investment Company Act of 1940
ASA's Poison Pill Has Remained in Continuous Effect for More Than 474 Days, Harming Shareholders and Violating Federal Law
Saba Believes the Anti-Shareholder Actions and Unlawful Steps Taken by Chair Mary Joan Hoene and Director William Donovan Underscore the Need for Immediate Board Change
Saba Capital Management, L.P. (together with certain of its affiliates, "Saba"), the largest common shareholder of ASA Gold and Precious Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASA#NYSE">ASA</a>) ("ASA" or the "Fund") with 17.2% ownership of the Fund's outstanding shares, today announced that it has filed a lawsuit in the United States District Court for the Southern District of New York (the "Court") against ASA and the legacy members of its Board of Directors (the "Board") – Mary Joan Hoene and William Donovan – regarding their readoption of an unlawful shareholder rights plan after the Court ruled that the previous shareholder rights plan violated the Investment Company Act of 1940 (the "'40 Act").

News

Legal

Saba Capital Files Lawsuit Against ASA Gold And Precious Metals And Its Legacy Directors Over Latest Unlawful Poison Pill; Says "ASA's Poison Pill Has Remained in Continuous Effect for More Than 474 Days, Harming Shareholders and Violating Federal Law"

Hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.
The publication, Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes, can be accessed at: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;index=1&amp;md5=93462c6dd5567a9a85f2e87e65dc5785">https://diabetesjournals.org/care/lookup/doi/10.2337/dc24-2841</a>.
CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing's syndrome) in patients with difficult-to-control type 2 diabetes. Part one of the study screened 1,057 patients at 36 sites across the United States. All patients had hemoglobin A1c greater than 7.5 percent, despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. Using a simple, standardized 1-mg dexamethasone suppression test (DST), 24 percent of these patients were found to have hypercortisolism. These findings were first presented at the American Diabetes Association Scientific Sessions in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.corcept.com%2Fnews-releases%2Fnews-release-details%2Fcorcept-announces-presentation-results-prevalence-phase-catalyst&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=June+2024&amp;index=2&amp;md5=12702a0e0a0fa0edd714c70e67cb4916">June 2024</a>.

CORT

Corcept Therapeutics Announces Publication Of Findings From Prevalence Phase Of CATALYST Trial In Diabetes Care

Southern States (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.97 by 6.19 percent. This is a 14.44 percent increase over earnings of $0.90 per share from the same period last year.

Earnings

Earnings Beats

SSBK

Southern States Q1 Adj EPS $1.03 Beats $0.97 Estimate

Mega Matrix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPU#NYSE">MPU</a>) announced that Yuder Pte. Ltd. ("Yuder"), a indirectly wholly owned subsidiary of it, has signed a Memorandum of Understanding (MOU) with Interactive Films LLC ("Interactive Films"), a subsidiary of Snail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) ("Snail Games"), a leading global independent developer and publisher of interactive digital entertainment. Under this MOU, both parties will leverage their respective strengths to establish a comprehensive collaboration framework for the joint development, production, and global distribution of short dramas, further enhancing their presence in the entertainment industry.

SNAL

Mega Matrix Subsidiary Yuder Signs MOU With Snail Games' Interactive Films To Jointly Develop, Produce, And Distribute Short Dramas Globally

On April 15, 2025, the Board of Directors of American Pacific Corporation (AMPAC), a subsidiary of NewMarket Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>), met and approved a capital investment of up to $100 million to expand its ammonium perchlorate production capabilities in support of growing solid rocket motor demand. This anticipated investment will allow AMPAC to construct an additional production line, increasing capacity by more than 50%. The increased capacity will allow AMPAC to meet the demand of U.S. military and space launch programs, while also addressing the needs of U.S. allies in these critical areas. The project remains subject to approval by NewMarket's board of directors, and is currently scheduled to be completed during 2026.

Newmarket's American Pacific Board Approves Capital Investment Of Up To $100M To Expand Ammonium Perchlorate Production Capabilities In Support Of Growing Solid Rocket Motor Demand

OREM, Utah, April 21, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wcbD5irC69fKfRIuX8183WQn2d5V4CJS_05Xrk_sqVXlPEwcGdkY3vzlkrlMTJ5DJtYmP0UWiskvmGagI5SrPtbdEPFk5tozJyoJkRfL-M0=">Complete Solaria, Inc.</a> d/b/a SunPower ("SunPower" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>), a leading solar technology, services, and installation company, today announced it is rebranding as SunPower. The company's ticker symbol will change from "CSLR" and "CSLRW" to "SPWR" and "SPWRW", respectively, effective April 22, 2025.

CSLR

Complete Solaria, Announces It Will Rebrand As SunPower And Will Change Its Ticker From CSLR to SPWR Effective April 22, 2025

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of&nbsp;Enhertu&nbsp;(5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab) as a first-line treatment in patients with HER2-positive <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic breast cancer</a>.
High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningful improvement in progression-free <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44891999/enhertu-plus-pertuzumab-demonstrated-highly-statistically-significant-and-clinically-meaningful-im" rel="noreferrer noopener">survival (PFS) compared to THP</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44650506/european-drug-regulator-approves-astrazenecas-two-flagship-cancer-drugs-for-breast-and-lung-cance" rel="noreferrer noopener">European Drug Regulator Approves AstraZeneca&#8217;s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings</a>
The PFS improvement was seen across all pre-specified patient subgroups with&nbsp;Enhertu&nbsp;in&nbsp;combination with pertuzumab.
The key secondary endpoint of overall survival (OS) was not mature at this planned interim analysis; however, interim OS data showed an early trend favoring the&nbsp;Enhertu&nbsp;combination compared with&nbsp;THP.
The second arm assessing&nbsp;Enhertu&nbsp;monotherapy versus THP remains blinded to patients and investigators and will continue to the final PFS analysis.
HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2, affecting 15-20% of patients with metastatic breast cancer.
While HER2-targeted therapies have improved outcomes, prognosis remains poor, with most patients experiencing disease progression within two years of 1st-line treatment with THP, which has been the standard of care for more than a decade.
Further, approximately one in three patients never go on to receive treatment following 1st-line therapy due to disease progression or death.
The safety profile of&nbsp;Enhertu&nbsp;in combination with pertuzumab was consistent with the known profiles of each therapy.
Enhertu&nbsp;is a specifically engineered HER2-directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>) and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Data from the combination arm of DESTINY-Breast09 will be presented at an upcoming medical meeting and shared with regulatory authorities.
Enhertu is already approved in more than 75 countries as the 2nd-line treatment for patients with HER2-positive breast cancer based on the results from the&nbsp;DESTINY-Breast03&nbsp;trial.
In January, the U.S. Food and Drug Administration (FDA) approved Enhertu&nbsp;for adult patients with breast cancer that has progressed on one or more endocrine therapies <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43273643/fda-approves-astrazeneca-daiichi-sankyos-enhertu-for-certain-type-of-breast-cancer-patients" rel="noreferrer noopener">in the metastatic setting</a>.
The FDA <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et.html#!" rel="noreferrer noopener">granted</a> the approval after securing Priority Review and Breakthrough Therapy Designation. It was based on results from the DESTINY-Breast06 Phase 3 trial.
Price Action: AZN stock is up 1.05% at $68.30 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44877490/tractor-supply-earnings-outlook-brightens-with-2025-profit-growth-potential-says-analyst" target="_blank" rel="noreferrer noopener">Tractor Supply Earnings Outlook Brightens With 2025 Profit Growth Potential, Says Analyst</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

General

DSKYF

DSNKY

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

Washington Trust Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WASH#NASDAQ">WASH</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.63 by 3.17 percent. This is a 4.69 percent decrease over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $59.00 million which beat the analyst consensus estimate of $53.16 million by 10.99 percent. This is a 86.33 percent increase over sales of $31.66 million the same period last year.

Earnings Misses

WASH

Washington Trust Bancorp Q1 Adj $0.61 Misses $0.63 Estimate, Sales $59.00M Beat $53.16M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Mizuho analyst Uy Ear initiated coverage on Tectonic Therapeutic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with an Outperform rating and announced a price target of $51. Tectonic Therapeutic shares closed at $17.02 on Thursday. <a href="https://www.benzinga.com/quote/TECX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Richard Choe initiated coverage on Dycom Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) with an Overweight rating and announced a price target of $200. Dycom Industries shares closed at $154.51 on Thursday. <a href="https://www.benzinga.com/quote/DY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Adrienne Yih initiated coverage on Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with an Equal-Weight rating and announced a price target of $71. Abercrombie &amp; Fitch shares closed at $72.98 on Thursday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Stephen Sheldon initiated coverage on Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Market Perform rating. Zillow shares closed at $62.57 on Thursday. <a href="https://www.benzinga.com/quote/Z/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with an Equal-Weight rating and announced a price target of $17. Staar Surgical shares closed at $16.89 on Thursday.  <a href="https://www.benzinga.com/quote/STAA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-1024x590.png" alt="" class="wp-image-879530" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35.png 1096w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

Trading Ideas

STAA

TECX

This Dycom Industries Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

CMPX

Compass Therapeutics Doses First Patient In Investigator Sponsored Trial Of Tovecimig For Patients With Biliary Tract Cancer

Dynex Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DX#NYSE">DX</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.33 by 118.18 percent. This is a 110 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $17.13 million which missed the analyst consensus estimate of $21.48 million by 20.25 percent. This is a 636.75 percent increase over sales of $(3.19 million) the same period last year.

Dynex Cap Q1 2025 GAAP EPS $(0.06) May Not Be Comparable To $0.33 Estimate, Sales $17.13M Miss $21.48M Estimate

SS Notes Vacasa Engaged in a "Thorough" Strategic Review Process Over the Course of Eight Months
Vacasa Urges Shareholders to Vote "FOR" the Proposed Merger with Casago at the Special Meeting Scheduled for April 29, 2025
Vacasa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) ("Vacasa" or the "Company"), a leading vacation rental management platform in North America, today announced that both leading independent proxy advisory firms – Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis &amp; Co. ("Glass Lewis") – recommend shareholders vote "FOR" the proposed merger with Casago. A Special Meeting of Vacasa's shareholders (the "Special Meeting") related to the proposed merger is scheduled for April 29, 2025.
In its report recommending support for the merger, ISS notes:1
<ul>
<li>"…[T]he board appears to have conducted a thorough review of strategic options, which lasted approximately eight months."</li>
<li>"The board and the special committee appear to have also conducted a reasonable process to determine whether [Davidson Kempner's] offers were, or could potentially result in, a ‘superior proposal.'"</li>
<li>"…[T]he special committee's requests for additional assurance of certainty and timing appear reasonable given [Davidson Kempner's] differing economic interests from those of common shareholders."</li>
<li>"…[T]he board's conclusion that Casago's offer has higher certainty of timing and completion appears reasonable."</li>
<li>"Given the thorough sales process and the challenging outlook on a standalone basis, the proposed merger with Casago appears to be the best combination of economics and certainty for shareholders."</li>
</ul>
CEO Rob Greyber said: "We are pleased that both ISS and Glass Lewis recognize the extensive, thorough process Vacasa engaged in, and that both support the Board's recommendation for our proposed merger with Casago. We strongly believe this transaction represents the best risk-adjusted outcome for our shareholders."

VCSA

Vacasa Announces That Both Leading Independent Proxy Advisory Firms, Institutional Shareholder Services And Glass, Lewis & Co, Recommend Shareholders Vote "For" The Proposed Merger With Casago. At Special Meeting Of Vacasa's Shareholders April 29, 2025.

Needham analyst Laura Martin reiterates Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and maintains $1126 price target.

Price Target

Reiteration

Analyst Ratings

NFLX

Needham Reiterates Buy on Netflix, Maintains $1126 Price Target

Contracts

AMTX

Aemetis Subsidiary, Universal Biofuels, Received $31M In Biodiesel Orders For May June And July

—Aerovate Board of Directors approves 1-for-35 reverse stock split—
WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders.
On April 18, 2025, the Board approved a final reverse stock split of Aerovate's common stock at a ratio of 1-for-35 in connection with the anticipated closing of the Merger. Following the Merger, the combined company's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market ("Nasdaq") on April 29, 2025, under the new name "Jade Biosciences, Inc.", ticker symbol "JBIO", CUSIP number 008064206 and ISIN number US0080642061.
The reverse stock split is expected to reduce the number of Aerovate's outstanding common stock from approximately 30.0 million shares to approximately 0.8 million shares. The number of shares of Aerovate's authorized common stock will not be affected by the reverse stock split. At the Special Meeting, Aerovate's stockholders approved an increase in the number of shares of Aerovate's authorized common stock from 150,000,000 shares to 300,000,000 shares in connection with the anticipated closing of the Merger. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of Aerovate common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a cash payment in lieu of such fractional share. The cash payment to be paid will be equal to the fraction of a share to which such stockholder would otherwise be entitled multiplied by the closing price per share as reported by The Nasdaq Stock Market LLC on April 28, 2025.
As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Aerovate's common stock underlying Aerovate's outstanding equity awards. There will be no change to the par value per share.
The previously announced special cash dividend (the "Cash Dividend") will not be affected by the reverse stock split. An aggregate Cash Dividend of $69.6 million, or an estimated $2.40 per share, will be payable in cash to Aerovate's stockholders of record as of April 25, 2025 based on their holdings as of that date prior to the reverse stock split. The estimated per share dividend is based on 28,985,019 shares of Aerovate's common stock outstanding as of April 18, 2025.
Following the closing of the Merger, Jade Biosciences' total issued and outstanding common stock is expected to be approximately 32.2 million shares, or approximately 60.6 million shares on a fully-diluted basis.&nbsp;

AVTE

Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences; Board Approves 1-for-35 Reverse Stock Split

In the preceding three months, 6 analysts have released ratings for Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Belden, revealing an average target of $127.5, a high estimate of $145.00, and a low estimate of $120.00. A decline of 6.02% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745236915_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Belden's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Lowers &#x7C;Buy &#x7C; $120.00&#x7C;$130.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Lowers &#x7C;Buy &#x7C; $120.00&#x7C;$130.00 &#x7C; 
&#x7C;Mark Delaney &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $120.00&#x7C;$139.00 &#x7C; 
&#x7C;Chris Dankert &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $145.00&#x7C;$155.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $130.00&#x7C;$130.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $130.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Belden. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Belden compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Belden's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Belden's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Belden analyst ratings.</a>
<h2>Get to Know Belden Better</h2>
Belden Inc provides signal transmission products to distributors, end-users, installers, and original equipment manufacturers. The firm operates in two segments - Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions segment is a provider in network infrastructure and broadband solutions, as well as cabling and connectivity solutions for commercial audio/video and security applications. Automation Solutions segment provides network infrastructure and digitization solutions to enable customers to make data-based business decisions. It operates in Americas, EMEA and APAC, out of which maximum revenue from Americas.
<h3>Key Indicators: Belden's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Belden's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 20.83%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Belden's net margin is impressive, surpassing industry averages. With a net margin of 8.77%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Belden's ROE stands out, surpassing industry averages. With an impressive ROE of 4.62%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.75%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.97, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Belden In The Eyes Of 6 Experts

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Option Care Health, revealing an average target of $38.4, a high estimate of $41.00, and a low estimate of $35.00. This current average has increased by 9.71% from the previous average price target of $35.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745236896_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Option Care Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $38.00&#x7C;$38.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $41.00&#x7C;$40.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $38.00&#x7C;$33.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$38.00 &#x7C; 
&#x7C;Brian Tanquilut &#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $35.00&#x7C;$26.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Option Care Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Option Care Health compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Option Care Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Option Care Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPCH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Option Care Health analyst ratings.</a>
<h2>About Option Care Health</h2>
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
<h3>Breaking Down Option Care Health's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Option Care Health's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 19.75%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Option Care Health's net margin is impressive, surpassing industry averages. With a net margin of 4.47%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Option Care Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 4.25%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Option Care Health's ROA stands out, surpassing industry averages. With an impressive ROA of 1.76%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Option Care Health's debt-to-equity ratio is below the industry average. With a ratio of 0.87, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OPCH

Breaking Down Option Care Health: 5 Analysts Share Their Views

In the last three months, 12 analysts have published ratings on Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.0, a high estimate of $53.00, and a low estimate of $42.00. A decline of 4.8% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745236883_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Fifth Third Bancorp by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Konrad &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $42.00&#x7C;$47.00 &#x7C; 
&#x7C;David George &#x7C;Baird &#x7C;Maintains &#x7C;Outperform &#x7C; $47.00&#x7C;$47.00 &#x7C; 
&#x7C;Vivek Juneja &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $42.00&#x7C;$49.00 &#x7C; 
&#x7C;Whit Mayo &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$54.00 &#x7C; 
&#x7C;Keith Horowitz &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $43.00&#x7C;$52.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $52.00&#x7C;$57.00 &#x7C; 
&#x7C;Terry McEvoy &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $51.00&#x7C;$51.00 &#x7C; 
&#x7C;Gerard Cassidy &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $47.00&#x7C;$47.00 &#x7C; 
&#x7C;Peter Winter &#x7C;DA Davidson &#x7C;Raises &#x7C;Neutral &#x7C; $50.00&#x7C;$49.00 &#x7C; 
&#x7C;Gerard Cassidy &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $47.00&#x7C;$47.00 &#x7C; 
&#x7C;Scott Siefers &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $53.00&#x7C;$54.00 &#x7C; 
&#x7C;Brian Foran &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $52.00&#x7C;$51.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fifth Third Bancorp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fifth Third Bancorp compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Fifth Third Bancorp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fifth Third Bancorp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FITB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fifth Third Bancorp analyst ratings.</a>
<h2>Unveiling the Story Behind Fifth Third Bancorp</h2>
Fifth Third Bancorp is a diversified financial-services company headquartered in Cincinnati. The company has over $210 billion in assets and operates numerous full-service banking branches and ATMs throughout Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, and North Carolina.
<h3>Breaking Down Fifth Third Bancorp's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Fifth Third Bancorp's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.54%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Fifth Third Bancorp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.65%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Fifth Third Bancorp's ROE stands out, surpassing industry averages. With an impressive ROE of 2.67%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Fifth Third Bancorp's ROA excels beyond industry benchmarks, reaching 0.22%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.09, Fifth Third Bancorp adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FITB

Demystifying Fifth Third Bancorp: Insights From 12 Analyst Reviews

Tempest Therapeutics, Inc. - Common Stock

TPST

Tempest Receives FDA Orphan Drug Designation For TPST-1495 To Treat Patients With Familial Adenomatous Polyposis

In the latest quarter, 6 analysts provided ratings for Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $83.83, a high estimate of $97.00, and a low estimate of $70.00. This current average has decreased by 5.09% from the previous average price target of $88.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1745236871_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Texas Capital Bancshares is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Stephen Scouten &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $74.00&#x7C;$84.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $70.00&#x7C;$73.00 &#x7C; 
&#x7C;Wood Lay &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $95.00&#x7C;$100.00 &#x7C; 
&#x7C;Matt Olney &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Overweight &#x7C; $97.00&#x7C;$102.00 &#x7C; 
&#x7C;Anthony Elian &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $80.00&#x7C;$81.00 &#x7C; 
&#x7C;Gary Tenner &#x7C;DA Davidson &#x7C;Lowers &#x7C;Neutral &#x7C; $87.00&#x7C;$90.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Texas Capital Bancshares. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Texas Capital Bancshares compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Texas Capital Bancshares's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Texas Capital Bancshares's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TCBI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Texas Capital Bancshares analyst ratings.</a>
<h2>Discovering Texas Capital Bancshares: A Closer Look</h2>
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment excluding mortgage finance loans and other national lines of business. The bank operates in Texas main metropolitan areas like Austin Dallas Fort Worth Houston and San Antonio.
<h3>Texas Capital Bancshares: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Texas Capital Bancshares's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 9.42%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Texas Capital Bancshares's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 15.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Texas Capital Bancshares's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.38%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Texas Capital Bancshares's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.14%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Texas Capital Bancshares's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.45, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Boqii Holding

Noticias

Últimas noticias sobre Boqii Holding (AMEX:BQ) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL